Celcuity Inc. announced on July 30, 2025, the pricing of its concurrent underwritten public offerings, which are expected to generate approximately $248.7 million in net proceeds. The offerings include $175 million aggregate principal amount of 2.750% convertible senior notes due 2031 and 1,836,842 shares of common stock at $38.00 per share, along with pre-funded warrants for up to 400,000 shares.
The convertible notes have an initial conversion rate of 19.4932 shares of common stock per $1,000 principal amount, equivalent to an initial conversion price of approximately $51.30 per share, representing a 35% premium over the common stock offering price. The company elected to settle conversions in shares of common stock with cash in lieu of fractional shares.
The net proceeds, after deducting underwriting discounts and estimated offering expenses, are designated for working capital and general corporate purposes. These purposes include funding clinical trial expenditures, commercial launch preparations, research and development, and other strategic initiatives, providing substantial financial flexibility for Celcuity.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.